Eyewire News: The Podcast

Highlights from the last 6 months of 2025 include advancements of emerging technologies in glaucoma, the first pharmacologic treatment for myopia in Europe, the expansion of labels for anti-VEGF treatments, and the release of the DEWS III report exploring the diagnosis and management of dry eye disease.  Learn more about your ad choices. Visit megaphone.fm/adchoices

There were several advancements made during the first 6 months of 2025, including the first FDA approval for neurodegenerative disease MacTel; the approval of a first-of-its-kind drug for dry eye disease; advancements in premium IOLs; the approval of an excimer laser platform, and the launch of a new presbyopia drop. Learn more about your ad choices. Visit megaphone.fm/adchoices

Aldeyra provides an update on the timing of its dry eye disease treatment candidate reproxalap; Ocular Therapeutix pursues an accelerated NDA pathway for wet AMD therapy Axpaxli; and companies with late-stage drug candidates announce FDA submission plans.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Companies with plans to commercialize glaucoma technologies in the US reach clinical milestones; Haag-Streit announces the global launch of a new Indirect ROP Laser Module; and EyeYon Medical gets approval to initiate a US clinical study of its EndoArt corneal implant.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Several new technologies are emerging that aim to transform the way glaucoma is treated and managed. Many of these technologies are now available to patients outside of the United States, with the goal of expanding availability to the US and beyond.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Bausch + Lomb outlines a  strategic path to innovation and growth at its Investor Day; Apellis reports new 5-year data examining Syfovre and GA progression; and two global organizations for restoring sight merge.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Sydnexis receives another regulatory approval for its childhood myopia eye drop; Eli Lilly makes two major investments in ophthalmology; and Nanoscope reports new long-term data for its intravitreal optogenetic therapy for RP. Learn more about your ad choices. Visit megaphone.fm/adchoices

Leaders of several ophthalmic companies provide updates on their pipeline and new products in this special edition of Eyewire News the Podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices

Leaders of several ophthalmic companies provide updates on their pipeline and new products in this special edition of Eyewire News the Podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices

EyewireTV reports on new products and breaking news live from thee American Academy of Ophthalmology meeting in Orlando. Learn more about your ad choices. Visit megaphone.fm/adchoices

Uday Devgan, MD, shares his experience performing the world’s first robotic cataract surgery; Konan Medical receives CE Mark for its objectiveFIELD Analyzer perimetry device; and Biotech Healthcare launches a new full visual range EDOF IOL.  Learn more about your ad choices. Visit megaphone.fm/adchoices

A first-of-its-kind presbyopia eye drop is now commercially available; Lumibird introduces ICL Guru Integration on its ultrasound platform; and the makers of gene therapy candidates for retinal diseases provide clinical updates. Learn more about your ad choices. Visit megaphone.fm/adchoices

Industry executives discuss future innovations and breakthroughs that are poised to reshape the future of ophthalmic care.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Industry executives discuss future innovations and breakthroughs that are poised to reshape the future of ophthalmic care.  Learn more about your ad choices. Visit megaphone.fm/adchoices

EyewireTV reports on new products and breaking news live from the ESCRS Congress in Copenhagen.  Learn more about your ad choices. Visit megaphone.fm/adchoices

A proposal by the Trump Administration calls for cuts to the National Institutes of Health and consolidation of the federal government’s 27 institutes into just eight. This includes folding the National Eye Institute into a new broader institute on neuroscience and brain research. Ophthalmic leaders discuss what the vision care advocacy community is doing to combat proposed cuts to the National Ey...

Several companies with treatment candidates for retinal diseases provide clinical updates; Nicox releases new phase 3 data for its investigational glaucoma eye drop; the first patient is implanted with Ocumetics’ novel accommodating lens; and ASCRS provides details for its second annual Business of Refractive Cataract Surgery Summit. Learn more about your ad choices. Visit megaphone.fm/adchoices

Ciliatech obtains CE certification for the Intercil Uveal Spacer surgical implant; Zeiss receives CE mark for a new device that uses AI to automate OCT assessment; and the FDA extends the target action dates for two Eylea HD submissions. Learn more about your ad choices. Visit megaphone.fm/adchoices

Leaders from the Tear Film and Ocular Surface Society discuss the biggest takeaways from the recently released TFOS DEWS III report. Learn more about your ad choices. Visit megaphone.fm/adchoices

Charles Wykoff, MD, PhD, shares his experience performing the first commercial case for a patient with MacTel; VSY Biotechnology launches its Enova Hydrophobic IOLs with a new preloaded delivery system; and an app is launched that syncs AI directly to leading OCT devices. Learn more about your ad choices. Visit megaphone.fm/adchoices

Alcon makes a major acquisition to expand its refractive portfolio; the CEO of Lenz Therapeutics joins us to discuss the FDA approval of a new presbyopia drop; and the optical industry braces for major changes as new reciprocal tariffs are set to begin this week.   Learn more about your ad choices. Visit megaphone.fm/adchoices

Alcon launches its recently approved dry eye drug Tryptyr; a potential $1 billion deal is made to advance extended-release therapies for eye diseases; and two companies with late-stage AMD drug candidates complete phase 3 enrollment. Learn more about your ad choices. Visit megaphone.fm/adchoices

Harrow enters a deal to expand it biosimilar pharma portfolio; the first gene-agnostic therapy to restore vision in RP patients advances; and Aldeyra provides an update on its dry eye drug candidate reproxalap. Learn more about your ad choices. Visit megaphone.fm/adchoices

Leading ophthalmologists share summaries of their presentations live from thee AECOS Summer Symposium.     Learn more about your ad choices. Visit megaphone.fm/adchoices